MARKET

SMMT

SMMT

Summit Therapeutics Inc
NASDAQ
24.12
+0.50
+2.12%
After Hours: 24.25 +0.13 +0.54% 19:39 04/30 EDT
OPEN
22.98
PREV CLOSE
23.62
HIGH
24.35
LOW
22.84
VOLUME
4.37M
TURNOVER
--
52 WEEK HIGH
36.91
52 WEEK LOW
2.100
MARKET CAP
17.79B
P/E (TTM)
-78.3117
1D
5D
1M
3M
1Y
5Y
1D
Summit Therapeutics Inc <SMMT.OQ> expected to post a loss of 9 cents a share - Earnings Preview
Reuters · 1d ago
Analysts Are Bullish on These Healthcare Stocks: Summit Therapeutics (SMMT), Altimmune (ALT)
TipRanks · 1d ago
Why Is Summit Therapeutics Stock Trading Higher On Monday?
Benzinga · 2d ago
Summit Therapeutics Price Target Maintained With a $40.00/Share by JMP Securities
Dow Jones · 2d ago
JMP Securities Reiterates Market Outperform on Summit Therapeutics, Maintains $40 Price Target
Benzinga · 2d ago
Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday
Benzinga · 2d ago
Truist Financial Sticks to Their Buy Rating for Summit Therapeutics (SMMT)
TipRanks · 2d ago
Should You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat?
NASDAQ · 2d ago
More
About SMMT
More
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Recently
Symbol
Price
%Change

Webull offers Summit Therapeutics Inc stock information, including NASDAQ: SMMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SMMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SMMT stock methods without spending real money on the virtual paper trading platform.